Company Long-Term Loans and Borrowings: Evoke Pharma, Inc (EVOK)

Public company logo of Evoke Pharma Inc. (EVOK)

Evoke Pharma, Inc. (EVOK) has transitioned to the sale of its nasal product Gimoti, leveraging a network of counterparties to drive profit growth without capital expenditures. This chart of the current share price reflects the asset's dynamics, where the indicator stands at 0.00. Research efficiency is increasing through the digitalization of data collection, while the environmental footprint remains minimal due to the specific nature of biotechnological operations.

EVOK Evoke Pharma, Inc. Company Long-Term Debts (07/04/2022 - 12/27/2025)

Evoke Pharma, Inc (EVOK) - metric breakdowns and financial figures

- market price and analyst price targets:
Stock Price evokepharma.com|EVOK - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Evoke Pharma|EVOK - Total Company Value
- book capitalization information:
Accounting Value per Share Evoke Pharma|EVOK - Book Capitalization|Market Capitalization to Book Value Ratio evokepharma.com|EVOK - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Evoke Pharma, Inc.|EVOK - Long-Term Debt to Capital|Short-Term Indebtedness to Equity Evoke Pharma Inc|EVOK - Company Aggregate Debts|Debts to Net Assets Evoke Pharma|EVOK - Company Long-Term Liabilities|Amount of Current Liabilities Evoke Pharma|Immediate Liquidity evokepharma.com
- earnings and multiples data:
EVOK - Net Income
Summary company analytics:EVOK evokepharma.com
Brand item of Evoke Pharma, Inc

Evoke Pharma, Inc. (EVOK) focuses on developing innovative nasal therapies for the treatment of gastroparesis. The corporation's long-term loans and borrowings reflect the total liabilities with a maturity exceeding one year. This metric allows for an assessment of the debt load and the capital's resilience to interest rate fluctuations. A reduction in borrowings strengthens the financial base, although it may slow brand expansion. A stable debt obligation chart confirms the fundamental strength of the stock's market value.

Competitor analysis for Evoke Pharma, Inc.

Company Long-Term Debts phathompharma.com PHAT|TERN - Company Long-Term Debt|Company Long-Term Loans and Borrowings IRWD (Ironwood Pharmaceuticals)|curanexpharma.com (CURX) - Company Long-Term Debt|Company Long-Term Liabilities Immuron|ENTO (Entero Therapeutics Inc.) - Company Long-Term Debts|Company Long-Term Debts RedHill|Company Long-Term Liabilities PALI (Palisade Bio, Inc.)|JAGX (Jaguar Health Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts BIOR (Progenity)|Long-Term Indebtedness Morphic Holding Corp